General MedicationsINJECTIONGeneric
LIPOSYN II 20%
SAFFLOWER OIL; SOYBEAN OIL
Standard Dose
10%;10% (10GM/100ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview LIPOSYN II 20% is listed in Drugs@FDA under application 018991 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient SAFFLOWER OIL; SOYBEAN OIL Form and strength INJECTABLE;INJECTION - 10%;10% (10GM/100ML) Sponsor HOSPIRA Submission history Latest submission status date: 2003-04-14 00:00:00.
Structured Monograph
Clinical summary
Approval overview LIPOSYN II 20% is listed in Drugs@FDA under application 018991 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient SAFFLOWER OIL; SOYBEAN OIL Form and strength INJECTABLE;INJECTION - 10%;10% (10GM/100ML) Sponsor HOSPIRA Submission history Latest submission status date: 2003-04-14 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.